JP2015529657A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015529657A5 JP2015529657A5 JP2015525760A JP2015525760A JP2015529657A5 JP 2015529657 A5 JP2015529657 A5 JP 2015529657A5 JP 2015525760 A JP2015525760 A JP 2015525760A JP 2015525760 A JP2015525760 A JP 2015525760A JP 2015529657 A5 JP2015529657 A5 JP 2015529657A5
- Authority
- JP
- Japan
- Prior art keywords
- conditions
- cancer
- diseases
- prevention
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 230000002265 prevention Effects 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- 241000222722 Leishmania <genus> Species 0.000 claims 2
- 210000002784 stomach Anatomy 0.000 claims 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims 1
- 206010027654 Allergic conditions Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 201000003076 Angiosarcoma Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 1
- 208000005243 Chondrosarcoma Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 1
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 1
- 208000007465 Giant cell arteritis Diseases 0.000 claims 1
- 208000001258 Hemangiosarcoma Diseases 0.000 claims 1
- 241000711549 Hepacivirus C Species 0.000 claims 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims 1
- 241000725303 Human immunodeficiency virus Species 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010024229 Leprosy Diseases 0.000 claims 1
- 206010024305 Leukaemia monocytic Diseases 0.000 claims 1
- 241000186359 Mycobacterium Species 0.000 claims 1
- 201000004404 Neurofibroma Diseases 0.000 claims 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000025747 Rheumatic disease Diseases 0.000 claims 1
- 241000700584 Simplexvirus Species 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 206010044688 Trisomy 21 Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000011149 active material Substances 0.000 claims 1
- 206010002022 amyloidosis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000000981 epithelium Anatomy 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 210000004602 germ cell Anatomy 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 210000003128 head Anatomy 0.000 claims 1
- 230000001900 immune effect Effects 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 claims 1
- 230000004968 inflammatory condition Effects 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 208000037906 ischaemic injury Diseases 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000000867 larynx Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 201000005249 lung adenocarcinoma Diseases 0.000 claims 1
- 208000037841 lung tumor Diseases 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 210000004324 lymphatic system Anatomy 0.000 claims 1
- 201000004792 malaria Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000002503 metabolic effect Effects 0.000 claims 1
- 201000006894 monocytic leukemia Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 210000003739 neck Anatomy 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 244000045947 parasite Species 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 230000000552 rheumatic effect Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 206010043207 temporal arteritis Diseases 0.000 claims 1
- 230000001732 thrombotic effect Effects 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 201000008827 tuberculosis Diseases 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
- 239000003435 antirheumatic agent Substances 0.000 description 2
- 239000002988 disease modifying antirheumatic drug Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 229960004171 hydroxychloroquine Drugs 0.000 description 1
- 229960000681 leflunomide Drugs 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- 229960001940 sulfasalazine Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12005716.1 | 2012-08-07 | ||
| EP12005716 | 2012-08-07 | ||
| PCT/EP2013/002032 WO2014023385A1 (en) | 2012-08-07 | 2013-07-10 | Pyridopyrimidine derivatives as protein kinase inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018076582A Division JP2018150307A (ja) | 2012-08-07 | 2018-04-12 | プロテインキナーゼ阻害剤としてのピリドピリミジン誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015529657A JP2015529657A (ja) | 2015-10-08 |
| JP2015529657A5 true JP2015529657A5 (enExample) | 2017-09-28 |
| JP6374384B2 JP6374384B2 (ja) | 2018-08-15 |
Family
ID=48782275
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015525760A Expired - Fee Related JP6374384B2 (ja) | 2012-08-07 | 2013-07-10 | プロテインキナーゼ阻害剤としてのピリドピリミジン誘導体 |
| JP2018076582A Pending JP2018150307A (ja) | 2012-08-07 | 2018-04-12 | プロテインキナーゼ阻害剤としてのピリドピリミジン誘導体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018076582A Pending JP2018150307A (ja) | 2012-08-07 | 2018-04-12 | プロテインキナーゼ阻害剤としてのピリドピリミジン誘導体 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9725462B2 (enExample) |
| EP (1) | EP2882746B1 (enExample) |
| JP (2) | JP6374384B2 (enExample) |
| CN (1) | CN104507942B (enExample) |
| AR (1) | AR092365A1 (enExample) |
| AU (1) | AU2013301865B2 (enExample) |
| CA (1) | CA2881279C (enExample) |
| ES (1) | ES2618004T3 (enExample) |
| IL (1) | IL237073A (enExample) |
| WO (1) | WO2014023385A1 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015511245A (ja) * | 2012-02-23 | 2015-04-16 | アッヴィ・インコーポレイテッド | ピリドピリミジノン系キナーゼ阻害薬 |
| EP2882746B1 (en) * | 2012-08-07 | 2016-12-07 | Merck Patent GmbH | Pyridopyrimidine derivatives as protein kinase inhibitors |
| KR20140027714A (ko) * | 2012-08-27 | 2014-03-07 | 주식회사 홍인터내셔날 | 외부 디바이스와 연동하는 다트 게임 장치 |
| WO2017012559A1 (zh) * | 2015-07-21 | 2017-01-26 | 广州再极医药科技有限公司 | 稠环嘧啶类化合物、中间体、其制备方法、组合物和应用 |
| AU2017296289A1 (en) | 2016-07-12 | 2019-01-31 | Revolution Medicines, Inc. | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors |
| PE20191541A1 (es) | 2016-12-22 | 2019-10-23 | Calithera Biosciences Inc | Composiciones y metodos para inhibir la accion de la arginasa |
| CN110431134A (zh) | 2017-01-23 | 2019-11-08 | 锐新医药公司 | 作为变构shp2抑制剂的吡啶化合物 |
| JP7240319B2 (ja) | 2017-01-23 | 2023-03-15 | レヴォリューション・メディスンズ，インコーポレイテッド | アロステリックｓｈｐ２阻害剤としての二環式化合物 |
| JOP20190272A1 (ar) | 2017-05-22 | 2019-11-21 | Amgen Inc | مثبطات kras g12c وطرق لاستخدامها |
| WO2019014513A1 (en) * | 2017-07-13 | 2019-01-17 | Syros Pharmaceuticals, Inc. | INHIBITORS OF KINASES TAM |
| AR112797A1 (es) | 2017-09-08 | 2019-12-11 | Amgen Inc | Inhibidores de kras g12c y métodos para utilizarlos |
| EP3694848A1 (en) | 2017-10-12 | 2020-08-19 | Revolution Medicines, Inc. | Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors |
| WO2019100106A1 (en) * | 2017-11-24 | 2019-05-31 | The University Of Sydney | Antibacterial compounds and methods of use thereof |
| TW201927791A (zh) | 2017-12-15 | 2019-07-16 | 美商銳新醫藥公司 | 作為變構shp2抑制劑的多環化合物 |
| WO2019213516A1 (en) | 2018-05-04 | 2019-11-07 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| JP7369719B2 (ja) | 2018-06-12 | 2023-10-26 | アムジエン・インコーポレーテツド | ＫＲａｓ Ｇ１２Ｃ阻害剤及びそれを使用する方法 |
| JP6995025B2 (ja) | 2018-08-09 | 2022-02-04 | 株式会社豊田自動織機 | 太陽熱集熱管 |
| CN110833557A (zh) * | 2018-08-15 | 2020-02-25 | 广西梧州制药（集团）股份有限公司 | 吡唑并嘧啶衍生物在治疗肾小管肾炎的用途 |
| JP7377679B2 (ja) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法 |
| AU2020242287A1 (en) | 2019-03-21 | 2021-09-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A Dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| CA3225293A1 (en) | 2019-05-21 | 2020-11-26 | Amgen Inc. | Solid state forms |
| JP7357146B2 (ja) * | 2019-08-22 | 2023-10-05 | ブルーレイ セラピューティクス （シャンハイ） カンパニー，リミティド | アザヘテロアリール化合物及びその使用 |
| KR20220098759A (ko) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 키나제 억제제에 대해 내성을 획득한 암의 치료 방법 |
| EP4090663A1 (en) * | 2020-01-15 | 2022-11-23 | Blueprint Medicines Corporation | Map4k1 inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| BR112022016072A2 (pt) * | 2020-02-17 | 2022-10-04 | Alesta Therapeutics BV | Compostos moduladores de gcn2, sal farmaceuticamente aceitável, seus usos, e composição farmacêutica |
| WO2022048684A1 (zh) * | 2020-09-07 | 2022-03-10 | 武汉朗来科技发展有限公司 | Jnk抑制剂、其药物组合物和用途 |
| EP4228632A4 (en) * | 2020-10-16 | 2025-02-19 | Saint Louis University | Rev-erb agonists |
| WO2022079250A1 (en) | 2020-10-16 | 2022-04-21 | Merck Patent Gmbh | Compounds for the treatment of viral infections |
| WO2024243841A1 (zh) * | 2023-05-31 | 2024-12-05 | 西湖制药(杭州)有限公司 | 一种病毒蛋白酶抑制剂的结晶及用途 |
| CN117180122B (zh) * | 2023-11-02 | 2024-04-09 | 杭州湃肽生化科技有限公司 | 一种舒敏修复组合物及其应用 |
| WO2025240517A1 (en) * | 2024-05-14 | 2025-11-20 | Aleksia Therapeutics, Inc. | Cdk4 inhibitor naphthyridine compounds |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4959368A (en) * | 1986-02-24 | 1990-09-25 | Mitsui Petrochemical Industries Ltd. | Therapeutic agent for neurological diseases |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| BR9707495A (pt) | 1996-02-13 | 1999-07-27 | Zeneca Ltd | Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente |
| JP4464466B2 (ja) | 1996-03-05 | 2010-05-19 | アストラゼネカ・ユーケイ・リミテッド | ４―アニリノキナゾリン誘導体 |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| IL152682A0 (en) | 2000-05-31 | 2003-06-24 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
| CA2410562A1 (en) | 2000-07-07 | 2002-01-31 | Angiogene Pharmaceuticals Limited | Colchinol derivatives as angiogenesis inhibitors |
| JP2004502766A (ja) | 2000-07-07 | 2004-01-29 | アンギオジェン・ファーマシューティカルズ・リミテッド | 血管損傷剤としてのコルヒノール誘導体 |
| US7732446B1 (en) | 2004-03-11 | 2010-06-08 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| WO2007125405A2 (en) | 2006-05-01 | 2007-11-08 | Pfizer Products Inc. | Substituted 2-amino-fused heterocyclic compounds |
| US7834024B2 (en) | 2007-03-26 | 2010-11-16 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
| WO2009046448A1 (en) | 2007-10-04 | 2009-04-09 | Intellikine, Inc. | Chemical entities and therapeutic uses thereof |
| KR101773313B1 (ko) | 2008-04-16 | 2017-08-31 | 포톨라 파마슈티컬스, 인코포레이티드 | ｓｙｋ 또는 ＪＡＫ 키나제 억제제로서의 ２,６－디아미노-피리미딘－５－일－카르복스아미드 |
| EA021938B1 (ru) | 2008-05-01 | 2015-10-30 | Сертрис Фармасьютикалз, Инк. | Хинолины и их аналоги в качестве модуляторов сиртуина |
| TWI453207B (zh) | 2008-09-08 | 2014-09-21 | Signal Pharm Llc | 胺基三唑并吡啶，其組合物及使用其之治療方法 |
| WO2010063352A1 (en) | 2008-12-01 | 2010-06-10 | Merck Patent Gmbh | 2, 5-diamino-substituted pyrido [4, 3-d] pyrimidines as autotaxin inhibitors against cancer |
| ES2658290T3 (es) | 2009-10-29 | 2018-03-09 | Genosco | Inhibidores de cinasa |
| US8772301B2 (en) | 2009-12-18 | 2014-07-08 | Sunovion Pharmaceuticals, Inc. | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof |
| EP2882746B1 (en) * | 2012-08-07 | 2016-12-07 | Merck Patent GmbH | Pyridopyrimidine derivatives as protein kinase inhibitors |
-
2013
- 2013-07-10 EP EP13735205.0A patent/EP2882746B1/en active Active
- 2013-07-10 WO PCT/EP2013/002032 patent/WO2014023385A1/en not_active Ceased
- 2013-07-10 US US14/420,003 patent/US9725462B2/en not_active Expired - Fee Related
- 2013-07-10 JP JP2015525760A patent/JP6374384B2/ja not_active Expired - Fee Related
- 2013-07-10 ES ES13735205.0T patent/ES2618004T3/es active Active
- 2013-07-10 AU AU2013301865A patent/AU2013301865B2/en not_active Ceased
- 2013-07-10 CN CN201380041839.3A patent/CN104507942B/zh not_active Expired - Fee Related
- 2013-07-10 CA CA2881279A patent/CA2881279C/en active Active
- 2013-08-07 AR ARP130102804A patent/AR092365A1/es unknown
-
2015
- 2015-02-03 IL IL237073A patent/IL237073A/en active IP Right Grant
-
2018
- 2018-04-12 JP JP2018076582A patent/JP2018150307A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015529657A5 (enExample) | ||
| JP2015508086A5 (enExample) | ||
| JP2015508099A5 (enExample) | ||
| JP2015509512A5 (enExample) | ||
| JP2015508085A5 (enExample) | ||
| JP2016128501A5 (enExample) | ||
| JP2020528889A5 (enExample) | ||
| US7074826B2 (en) | R-NSAID esters and their use | |
| JP2019524883A5 (enExample) | ||
| JP2015511609A5 (enExample) | ||
| WO2016044331A1 (en) | Bicyclic compounds | |
| JP2012532874A5 (enExample) | ||
| JP2012072150A5 (enExample) | ||
| JP2018520205A5 (enExample) | ||
| JP2018518537A5 (enExample) | ||
| JP2014515013A5 (enExample) | ||
| JP2010523522A5 (enExample) | ||
| JP2014114295A5 (enExample) | ||
| RU2012103487A (ru) | Ингибирующие jak соединения на основе пиразолопиримидина и способы | |
| JP2016505058A5 (enExample) | ||
| JP2016512227A5 (enExample) | ||
| JP2014517051A (ja) | ジュウテリウム富化４−ヒドロキシ−５−メトキシ−ｎ，１−ジメチル−２−オキソ−ｎ−［（４−トリフルオロ−メチル）フェニル］−１，２−ジヒドロキノリン−３−カルボキサミド | |
| JP2015522037A5 (enExample) | ||
| JP2021046428A (ja) | Ｎｍｄａ受容体のモジュレーターとしてのピリドピリミジノン及びその使用 | |
| Abbas et al. | Novel substituted and fused pyrrolizine derivatives: Synthesis, anti-inflammatory and ulcerogenecity studies |